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Lck is a relevant target in chronic 
lymphocytic leukaemia cells whose 
expression variance is unrelated to 
disease outcome
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Kalakonda1 & Joseph R. Slupsky  1
Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) 
expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding 
region, receptor expression levels and signal capacity have all linked BCR on CLL cells to disease 
prognosis. Our previous work showed that the src-family kinase Lck is a targetable mediator of BCR 
signalling in CLL cells, and that variance in Lck expression associated with ability of BCR to induce signal 
upon engagement. This latter finding makes Lck similar to ZAP70, another T-cell kinase whose aberrant 
expression in CLL cells also associates with BCR signalling capacity, but also different because ZAP70 is 
not easily pharmacologically targetable. Here we describe a robust method of measuring Lck expression 
in CLL cells using flow cytometry. However, unlike ZAP70 whose expression in CLL cells predicts 
prognosis, we find Lck expression and disease outcome in CLL are unrelated despite observations 
that its inhibition produces effects that biologically resemble the egress phenotype taken on by CLL 
cells treated with idelalisib. Taken together, our findings provide insight into the pathobiology of CLL 
to suggest a more complex relationship between expression of molecules within the BCR signalling 
pathway and disease outcome.
Chronic lymphocytic leukaemia (CLL) is a heterogeneous malignancy of mature B lymphocytes. This disease is 
important because it is a common leukaemia among elderly adults in North America and Europe, and because of 
the significant morbidity and mortality associated with the progressive form of this disease. Several biomarkers 
have been identified that distinguish between indolent and progressive disease in CLL, and each has advantages 
and disadvantages according to the clinical information provided and ease of measurement1. However, none of 
these markers are useful for patient stratification with respect to the recent introduction of new therapies target-
ing Bcl2 and the B cell receptor (BCR) signalling pathway that have revolutionised treatment for this disease2.
As a marker distinguishing between CLL cells that have undergone the germinal centre reaction, mutational 
status of the IGHV genes coding for the BCR is one of the strongest predictors of overall survival in this dis-
ease1,3,4. Importantly, it is found that BCRs on CLL cells from different patients can be virtually identical with 
respect to IGHV genes and sequences, indicating a potential common mechanism of disease pathogenesis in CLL 
involving a B cell populations with limited BCR heterogeneity and/or selection of the malignant clone by a limited 
set of antigenic determinants5,6. Indeed, mutational status of the IGHV genes confer antigen specificity; BCRs 
derived from unmutated genes are polyreactive whereas those derived from mutated genes are monoreactive7. 
Also, CLL cells with unmutated or mutated IGHV genes respond differently to BCR engagement8, a response 
thought governed by the ability of BCR to enter lipid raft structures9. Nevertheless, later studies linked BCR 
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signalling capacity and evidence of engagement with markers of poor disease prognosis10–13. Interestingly, BCR 
signalling pathway proteins show high expression in CLL cells14–17, and some, including ZAP70, have been shown 
to have prognostic significance18,19. Considering that proteins such as Bruton’s tyrosine kinase (BTK) and Syk are 
also therapeutic targets17,20,21, it is possible that expression levels of other potential therapeutic targets within the 
BCR signalling pathway may also inform on CLL prognosis.
In this regard Lck may be an important consideration. Previous work performed by us22 and others23,24 show 
variable expression of this src-family kinase (SFK) in malignant cells from different patients with CLL without 
relation to disease parameters. Moreover, our work demonstrated Lck as a key mediator of BCR signalling in CLL 
cells, where expression levels of this SFK correspond with the strength of signal following BCR engagement22. 
Considering the demonstrated link between BCR signalling strength and poor disease outcome in CLL10,13,25, we 
reasoned that Lck levels may also correspond to disease outcome and warrant further investigation. Importantly, 
inhibition of Lck either using a specific inhibitor or siRNA-mediated knockdown blocks proximal and distal BCR 
signalling events in CLL cells, and removes their influence on overall cell survival. This phenomenon is reminis-
cent of the effects of 2 other BCR pathway inhibitors, idelalisib and ibrutinib, which inhibit PI3Kδ and Bruton’s 
tyrosine kinase (Btk), respectively26. The effectiveness of these agents in the therapy of CLL lies with their ability 
to promote lymphocytosis of malignant cells from proliferation centres26. Recent work from our lab27 suggests 
the mechanism used by idelalisib involves induction of lymphocyte egress through upregulation of the receptor 
for sphingosine 1-phosphate (S1PR1) and migration to sphingosine 1-phosphate (S1P), while others28,29 have 
demonstrated that the mechanism used by ibrutinib involves inhibition of chemokine- and BCR-induced integrin 
α4β1 adhesion to fibronectin and VCAM. Thus, Lck may be considered a biological target in the treatment of CLL 
in the same way targeting Btk and PI3Kδ are now.
The present study further defines Lck as a relevant target in CLL, and shows that inhibition of this SFK causes 
effects similar to those observed when CLL cells are treated with the phosphatidylinositol 3 kinase δ (PI3Kδ) 
inhibitor idelalisib. We also developed a robust flow cytometry-based technique to assess Lck expression, and used 
this assay to investigate the relationship between expression of this SFK and disease. However, our data show that 
Lck expression levels in CLL cells is unrelated to overall survival or time to first treatment. This result is surprising 
in light of our previous work showing Lck expression level is important for BCR signalling strength22, and implies 
that although Lck, like other kinases within the BCR signalling pathway, is targetable in CLL, measurement of its 
expression levels between patient samples is unlikely to be useful for stratifying BCR-targeted therapies.
Results
Lck expression in CLL cells varies between patient samples. In our previous work22 we observed 
variance in Lck expression within isolated CLL cells from patient samples that corresponded to BCR signalling 
capacity. However, a key limitation of the approach used was that measurement of Lck expression levels could not 
be related to disease parameters over larger cohorts of patient samples. To increase the consistency of Lck meas-
urement within the current study we developed a Western blot based method that quantitated expression levels 
of this SFK in purified CLL cells against standard amounts of recombinant Lck (Fig. 1a). We used this method to 
determine Lck expression in the malignant cells from 40 cases of CLL (Supplementary Table 1), and found a range 
of expression from very low (31.5 pg Lck/10 μg total cellular protein) to very high (235 pg Lck/10 μg total cellular 
protein) that was unrelated to IGHV mutation status.
Determination of Lck expression by Western blot is difficult and expensive owing to the need to purify CLL 
cells from T cell contamination, and then reliably quantitate Lck expression in these cells against recombi-
nant Lck. To simplify this determination we developed a method to detect intracellular Lck by flow cytometry. 
Figure 1b and c show that flow cytometry can be used to detect different levels of Lck expression in CLL cells, 
and there is a high degree of correlation between the Western blot and flow cytometric methods for determining 
Lck expression. We therefore used flow cytometry to determine Lck expression in CLL cells from a second larger 
cohort of patient samples.
To control for experimental variability with respect to day-to-day measurement of Lck expression we used 
reference samples, a single CLL case and normal cells from a buffy coat, that were examined with each tranche of 
patient samples. Lck expression in cells was normalised for all analyses to that in normal T cells within the buffy 
coat reference sample. Figure 2a shows the results of 17 separate measurement experiments of Lck expression 
in the normal B cells of the buffy coat reference sample, and in CLL and T cells from the patient sample. Our 
method of approach showed a high degree of reproducibility, Lck measured at consistently low levels in normal B 
cells (0.31 ± 0.03). Since normal peripheral B cells do not express Lck23 we suggest that the value determined is a 
measure of background non-specific staining of the anti-Lck antibody we used. Measurement of Lck expression 
within CLL cells from the patient reference sample showed similar reproducibility (0.49 ± 0.10), and the value 
recorded was significantly higher (P < 0.001) than that observed for normal B cells indicating specific binding of 
the anti-Lck antibody. A surprising observation was Lck expression within the T cells of the CLL patient reference 
sample. The value observed here was reproducible (1.24 ± 0.23) and higher than that of normal T cells.
Analysis of Lck expression within CLL cells from the entire second cohort of 134 patient samples showed 
a broad range of values (Fig. 2b, Supplementary Table 2). Some cases of CLL expressed virtually undetectable 
levels of Lck (i.e. the values recorded were less than or equal to those associated with normal B cells), whereas 
Lck expression in others exceeded that in normal T cells. Generally, we observed that Lck expression within CLL 
cells from the patient cohort was significantly greater than that in normal B cells (P < 0.001). Further analysis of 
Lck expression in CLL cells from the patient cohort in relation to either IGHV mutation (Fig. 2c) or disease stage 
(Fig. 2d) showed no correlation, indicating that Lck levels cannot be used as a surrogate marker for the former 
and are likely not affected during the course of disease progression. Finally, in concordance with our finding using 
the single CLL case above we found that Lck expression in T cells from the CLL patient cohort was significantly 
higher than that observed in T cells from normal individuals (P = 0.008).
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Inhibition of Lck in CLL cells induces expression of S1PR1 and migration to S1P, but does not 
affect chemotaxis induced by CCL21. We next sought to determine whether Lck could be a relevant tar-
get in CLL similar to PI3Kδ due to the proximal role this SFK plays in the BCR signalling pathway. Figure 3a com-
pares the effects of idelalisib and 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2d] pyrimidin -7-yl-cyclopentane 
(Lck-i) on S1PR1 expression on CLL cells. Both treatments induced significant upregulation of this receptor com-
pared to untreated controls, the extent of which seeming unrelated to whether Lck was expressed at high or low 
levels within affected CLL cells (Supplementary Figure 2a). As expected, both treatments also induce significant 
enhancement of CLL migration to S1P (Fig. 3b), an effect that seemed reliant upon the level of S1PR1 expressed 
by CLL cells (Supplementary Figure 2b). As a control experiment, we compared the effects of Lck-i to those of 
ibrutinib in an assay measuring CCL21-induced transendothelial migration because our previous work27 showed 
the latter inhibits this process. This experiment showed CLL cell treatment with Lck-i was ineffective at inhibiting 
CCL21 migration, while treatment with ibrutinib significantly inhibited this process (Fig. 3c). This experiment 
indicates that kinases, like Lck, that are targeted by Lck-i do not function within signalling pathways controlling 
chemokine-induced migration of CLL cells in the same way kinases like Btk, targeted by ibrutinib, do. Within a 
Figure 1. Variable Lck expression levels in CLL cells determined by Western blot and flow cytometry. (a) Western 
blot analysis of Lck expression in lysates of purified CLL cells. 10 μg of protein derived from lysates of CD19-
purified CLL cells was separated by SDS-PAGE and immunoblots probed with either anti-Lck mAbs or anti-
β-actin (as loading control). Varying amounts of purified recombinant Lck protein were used as standards to 
determine Lck levels in cell lysates. (b) Flow cytometry histograms of Lck expression in CLL cells derived from 
cases with known high and low levels. (c) Correlation of Lck expression in CLL cells determined by Western 
blot versus flow cytometry.
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broader interpretation the results of this section provide support for the notion of Lck as a relevant target because 
of the similar behaviour exhibited by CLL cells treated with Lck-i and idelalisib.
Lck expression is associated with in-vitro and in-vivo sensitivity to chemotherapy. Others have 
suggested that levels of Lck expression in haemic cells relate to responsiveness to chemotherapy30,31. To investi-
gate this possibility we used previously generated data measuring malignant cell sensitivity to glucocorticoid and 
fludarabine treatment in CLL32, using only those cases for which we had data on Lck expression. Whereas CLL 
cell treatment with dexamethasone induced similar levels of cell death between Lck high and low expressing cases 
(Fig. 4a), we found that CLL cells expressing low levels of Lck required greater concentrations of fludarabine to 
achieve 90% cell death (LC90) than did those expressing high levels of Lck (Fig. 4b). This in-vitro resistance to 
fludarabine therapy is supported by in-vivo data showing that patients whose CLL cells expressed low levels of Lck 
were less likely to achieve a partial or complete response when being treated with this drug (Table 1). Thus, Lck 
expression in CLL cells may be an important indicator of disease response to therapy.
Lck expression is not related to disease prognosis. The above data together with the demonstrated 
role of Lck as a mediator of BCR signalling capacity22 suggest that Lck expression within CLL cells may be use-
ful as a predictor of prognosis and/or outcome for this disease. Figures 5 and 6 show our investigation of this 
hypothesis. In the first instance we validated our cohort of patient samples and show that IGHV mutation status 
is a predictor of time to first treatment (TTFT) (Fig. 5a). However, division of patient samples into CLL cases with 
high or low Lck expression did not relate either to overall survival or to TTFT (Fig. 5b and c). For this analysis 
we chose the cut off value of 0.57 to divide cases into high and low expressing cases because this corresponded 
Figure 2. Measurement of Lck expression in CLL cells of patient samples by flow cytometry. (a) Box and whisker 
plots showing repeat measurements of Lck expression in normal B cells within a buffy coat samples from a single 
donor, and in T cells and malignant B cells from samples derived from a single patient with CLL. Lck expression 
in the cells illustrated by this experiment is normalised to that in normal T cells within the buffy coat sample. (b) 
Beeswarm plot of Lck expression in CLL cells, T cells from CLL patients, and B and T cells from normal patients. 
Statistical analysis was performed using a Mann-Whitney U test. “***” signifies a comparison of Lck expression 
between CLL cells and normal B cells, P < 0.001. “**” signifies a comparison of Lck expression between T cells 
from CLL patients and normal T cells, P = 0.008. (c) Comparison of Lck expression in UM- and M-CLL cells. 
(d) Comparison of Lck expression in CLL cells from patients with different stages of disease.
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approximately to the mean/median value of Lck expression in CLL cells regardless of whether we used the whole 
cohort of samples, or divided the cohort by M-/UM-CLL status (Fig. 2c) or by disease stage (Fig. 2d).
The data presented in Fig. 5 compare overall survival and TTFT from diagnosis. However, Lck expression 
potentially changes over the course of CLL, particularly if the cells are exposed to toll-like receptor antigens33. To 
take this into account we calculated overall survival and TTFT in patients using the sampling date rather than the 
date of diagnosis. Figure 6a and b show that no relationship exists between Lck expression and either of these two 
parameters within the cohort of patient samples we analysed. Furthermore, breakdown of the cohort into M- and 
UM-CLL cases and re-analysis of TTFT from sampling also failed to show significant relationship to high or low 
Figure 3. Lck inhibition induces expression of S1PR1 on CLL cells and their migration toward S1P. (a) CLL cells 
from 10 cases were examined immediately, or were cultured for 16 h with either idelalisib (1 μM), Lck-i (1 μM) 
or left untreated. All cells were examined by flow cytometry for S1PR1 levels. (b) CLL cells from four patients 
were incubated for 16 h with idelalisib (1 μM), Lck-i (1 μM) or left untreated (None), and then examined for 
migration toward S1P using HUVEC-coated transwells. The data are presented as migration index which is the 
quotient of the number of CD19 + cells transmigrating in the presence of S1P divided by that in its absence. 
(c) CLL cells from four patients were cultured with ibrutinib (1 μM), Lck-i (1 μM) or left untreated (None), 
and examined for migration toward CCL21 using HUVEC-coated transwells. Data are presented normalised 
to the level of CCL21-induced migration observed with untreated cells which is taken to be 100%. Statistical 
significance for all parts of this figure was determined using a Student’s t-test for paired data.
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expression levels of Lck (Fig. 6c and d). Taken together, these data show that although Lck is a key regulator of 
BCR signalling22, expression levels of this kinase do not predict disease prognosis.
Discussion
The aim of this study was to determine if Lck expression levels in CLL cells correlate with clinical outcome. This 
hypothesis is generated from previous work22 demonstrating that Lck is a key mediator of BCR signalling in CLL 
cells, and that BCR signalling strength in these cells is related to the level of this SFK that is present. However, we 
found no relationship between Lck expression and either overall survival or time to first treatment, even if patient 
samples were stratified into M- and UM-CLL subgroups.
The above finding is important relative to the work of others who have demonstrated a relationship between 
BCR signalling strength and progressive disease in CLL10,13,25. Given that several proteins within the BCR signal-
ling pathway are reported expressed at higher levels in CLL than in normal B cells14, that some of these proteins 
such as Btk and Syk are also therapeutic targets and that this pathway plays an important role in the pathogenesis 
of this disease, it is not unreasonable to postulate a correlation between expression of pathway proteins, BCR 
signalling strength and disease outcome. Indeed, expression of ZAP70 is correlated with ability to signal through 
Figure 4. Lck expression affects CLL cell sensitivity to fludarabine but not dexamethasone. CLL cell sensitivity 
to (a) dexamethasone (presented as % induction of cell death) or (b) fludarabine (presented as concentration 
(nM) where 90% of cells have undergone apoptosis, LC90) was compared between CLL cells from cases in cohort 
1 with high (>129 pg/10 μg total cellular protein) or low (<129 pg/10 μg total cellular protein) levels of Lck 
expression using data that corresponded to cases also used in Melarangi et al.32. Statistical significance for both 
parts of this figure was performed using a Mann-Whitney U-test.
NR PR CR Total
Low Lck 7 20 4 31
High Lck 0 17 7 24
Table 1. Treatment response in relation to Lck expression within CLL cohort 2. CLL cases divided into High 
and Low Lck expression, respectively defined as greater or lesser than the median value of normalized Lck 
expression (0.57), were analysed with respect to no response (NR), partial response (PR) and complete response 
(CR) to therapy consisting of chlorambucil and/or fludarabine and/or rituximab. Statistical analysis was 
performed using a χ2 test (P = 0.026, χ2 df = 7.289, 2).
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the BCR34,35, but its ability to enhance BCR signals is independent of its kinase activity25,36 indicating that inhib-
itors of ZAP70 may need to target protein interactions. High levels of Lyn expression are reported linked to 
shorter treatment-free survival in CLL19, and this kinase shows constitutive activation in CLL cells16. How this 
relates to BCR signalling strength is unclear because proximal signals such as phosphorylation of CD79 can be 
completely blocked by inhibitors of Lck which do not affect Lyn kinase activity22. Recently, a paper by Märklin 
et al.37 linked the anergic phenotype of CLL cells to NFAT2-driven expression of several genes including that 
coding for Lck. This paper is important because it suggests that high levels of Lck expression in CLL cells may 
predict favourable disease prognosis because BCR signalling anergy is associated with mutated IGHV genes8. 
The data provided by Märklin et al. support our findings that Lck is overexpressed in human CLL compared to 
normal B cells, however, whereas these same data show that low levels of Lck are associated with CLL cells from 
patients with aggressive disease, we find no such correlation of Lck expression with markers of poor prognosis 
Figure 5. Lck expression in CLL cells is not predictive of overall survival or TTFT determined from disease 
diagnosis in a cohort of patient samples. (a) Kaplan Meier plots showing time to first treatment (TTFT) from 
disease diagnosis in patients having CLL cells with mutated (M) and unmutated (UM) IGHV genes. (b and c) 
Kaplan Meier plots showing overall survival and TTFT from disease diagnosis in patients having CLL cells with 
high or low levels of Lck expression. High and Low Lck expression is determined as being either greater or lesser 
than the median value (normalized Lck expression of 0.57) for all samples within the cohort.
www.nature.com/scientificreports/
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in the cells from the cohorts of patient samples we analyzed. This discrepancy may be due to the nature of CLL 
cells studied by Märklin et al. where aggressive CLL refers to malignant cells derived from patients with Richter’s 
syndrome; we analysed no such cells in the current study. Moreover, the TCL mouse model of CLL used is similar 
to human UM-CLL with respect to the role of BCR on malignant cells in driving progressive disease38–40, and is an 
accepted paradigm of this type of disease41. In TCL1 CLL cells BCR signalling, although weak, is still present and 
conceivably mediated by Lck in the same way as we have demonstrated for human CLL cells22 because CD79 and 
Lck co-association can be demonstrated in BCR-stimulated cells37. With this in mind it is important to consider 
that LCK is not the only gene regulated by NFAT2 in the system studied37, and it is likely that the combination 
of regulated genes has functional consequence in producing BCR signalling anergy. In this context, our findings 
in the current study taken together with those of our previous work22 suggest that Lck expression is not per se 
responsible for mediating BCR anergy.
Interestingly, CLL cells expressing low levels of Lck required higher concentrations of fludarabine in vitro for 
effective induction of cell death than did CLL cells expressing high levels of Lck, and patients with these cells were 
less likely to have complete or partial response to this drug than patients with CLL cells expressing high levels of 
Lck. Thus, Lck expression may be an indicator of CLL cell resistance to chemotherapy and have importance for 
therapeutic decision making. Considering that fludarabine in combination with chlorambucil and rituximab is 
a front line therapy in CLL42, further study of this possibility is required to assess the value of Lck expression as 
a potential biomarker. Why Lck expression can be linked with disease resistance to chemotherapy but not have 
relationship to disease outcome in CLL is unclear. It is possible that Lck expression levels in CLL cells are affected 
by microenvironmental influences and may not be static in the same way other protein markers such as ZAP70 
are. This notion is supported by studies showing that Toll-like receptor (TLR) agonists provide cultured CLL cells 
with increased resistance to fludarabine43 and induce downregulation of Lck expression33. Activation of Lck may 
also be important. We acknowledge that a weakness of our study is lack of data regarding the activation state of 
this SFK in the malignant cells of the patient cohorts we had available. pY394-Lck antibodies are now commercially 
available that were not when we began this study. Although this antibody may be a useful tool for the detection 
of active Lck, it should be noted that interpretation of results generated using this reagent may be problematic for 
the following reasons: (1). Lck shares significant homology with Blk within their respective peptide sequences 
Figure 6. Lck expression in CLL cells is not predictive of overall survival or TTFT determined from sampling. (a 
and b) Kaplan Meier plots showing overall survival and TTFT from sampling in patients having CLL cells with 
high or low levels of Lck expression. (c) Kaplan Meier plot showing TTFT from sampling in patients having 
M-CLL cells with high or low levels of Lck expression. (d) Kaplan Meier plot showing TTFT from sampling 
in patients having UM-CLL cells with high or low levels of Lck expression. High and Low Lck expression is 
determined as being either greater or lesser than the median value (normalized Lck expression of 0.57) for all 
samples within the cohort.
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containing the homologous pY394 residue. Therefore, in cells such as in CLL cells44 where both Blk and Lck are 
expressed, a positive result may not specifically indicate active Lck. (2). The need to calculate pY394-Lck/total Lck 
ratios specifically in CLL cells also presents problems in our study where we use flow cytometry to detect Lck 
expression. The pY394-Lck antibody available is sold unconjugated, making its use with other antibodies in flow 
cytometry technically difficult.
Our method using flow cytometry to assess Lck levels in CLL cells is robust. We tested this method against 
Western blot measurement of Lck expression to show there is a high degree of concordance between the two 
methods. Importantly, the Western blot technique we used was accurate and precise because Lck levels within 
CLL cell lysates were standardized against recombinant Lck, and because equal protein loading for each sample 
was ensured by protein assay and then confirmed by Western blotting for β-actin. A drawback of this approach 
is the requirement for CLL cells to be highly purified prior to lysis to eliminate the contribution of T and NK 
cell contamination to the level of Lck measured by Western blotting. Measuring Lck by flow cytometry is eas-
ier than by Western blot, particularly because CLL cells can be directly identified by antigen expression. An 
added advantage is that Lck can also be measured in accompanying T cells for comparison with known positives. 
Standardization in flow cytometry is applied by the inclusion of reference samples that are assessed with each lot 
of target CLL tests measured. In our case we included PBMCs isolated from a normal blood donor buffy coat, as 
well as cells from a CLL patient taken as a single sample. These reference samples were then analysed with each 
of the 17 lots of CLL cell tests from the cohort of patient samples we employed for this study. We normalised Lck 
expression in all cell types against that observed within the T cells of the reference PBMCs. As expected45, normal 
B cells within the reference PBMCs have very low levels of Lck. The mouse B-1 B cell subset is reported to express 
Lck, where it participates in regulating BCR signal transduction46. Although Lck expression in the human equiv-
alent of B-1 cells is yet to be described, it is unlikely that our method detects any contribution because this subset 
of B cells comprises less than 10% of total circulating B cells47, and we did not specifically design our antibody 
panel to detect B-1 cells. Therefore, the low level of Lck expression we show for normal B cells can be taken as the 
lower limit of detection for our method. Interestingly, we observed that Lck levels in T cells from CLL patients was 
greater than that in T cells from normal individuals. This result is similar to observations made with ZAP7048, and 
is consistent with reports showing that this protein is expressed at higher levels in T cells from CLL patients than 
in T cells from normal donors48,49. Taken together, overexpression of Lck and ZAP70 in T cells of CLL patients 
could be reflective of either T cell dysfunction related to inability to form an immunological synapse that has been 
reported associated with this disease50,51, or to the development of T cell populations that are skewed towards a 
memory and/or senescent CD8+ T cell phenotype52,53.
A potential limitation of our study is the high proportion of M- to UM-CLL cases (approximately 2:1) within 
cohort 2 of the patient samples. Although this ratio is representative of disease in CLL1, it is possible that the high 
proportion of M-CLL cases may obscure the value of Lck expression with respect to disease prognosis. This is 
because Lck levels are likely not relevant to the potentially large proportion of cases within this subgroup where 
the malignant cells are reported to be anergic to BCR engagement54. Indeed, this notion finds resonance with 
observations that Lck levels have no prognostic value within the M-CLL subgroup. The probable influence of the 
large proportion of M-CLL cases is further supported by experiments comparing Lck expression between the M- 
and UM-CLL subgroups, and between CLL cells from patients with different stages of disease; no clear difference 
in Lck levels was observed. In addition, it is possible that high levels of Lck are associated with aggressive disease 
within the cohort of UM-CLL samples available to us (we observed clear poor prognosis associated with this sub-
group), but any such interpretation must be taken with extreme caution until more cases can be added because 
our data are not significant in relation to Lck expression and clinical outcome within this subgroup. Our inability 
to find meaningful correlation could also be the result of choosing the Lck expression threshold close to the mean 
of the cohort. We do not think this is the case because reanalysis of the data to only consider very high and very 
low Lck expression did not show statistical significance with respect to overall survival or TTFT.
As a proximal regulator of BCR signalling it is plausible that inhibition of Lck will have clinical value, a concept 
that is enhanced by our previous demonstration that the Lck inhibitor we used has specificity for Lck but not for 
Lyn and that it blocks BCR signalling22. The experiments we present in this manuscript suggest that Lck inhibitors 
may be biologically useful because treatment of CLL cells with Lck-i promotes expression of S1PR1 to facilitate 
migration to S1P. The mechanism we propose for Lck-i is similar to that of idelalisib which we show in the current 
manuscript, and which we have previously shown27, induces upregulation of S1PR1 and migration to S1P in CLL 
cells. This notion is supported by observations reported here that treating CLL cells with Lck-i does not affect 
chemokine-induced migration, an effect that is similar to our reported observations of the effect of idelalisib on 
the same phenomenon27. In contrast, such migration is blocked by CLL cell treatment with ibrutinib, an effect 
that is reported to be mediated by inhibition of chemokine receptor-induced integrin α4β1 activation27–29, and a 
compound which we have shown neither influences expression of S1PR1 nor CLL cell migration to S1P27. Thus, 
Lck is not involved in chemokine receptor-induced signals, and Lck-i does not work in the same way as ibrutinib. 
The similarity of effects induced by CLL cell treatment with Lck-i and idelalisib does suggest that if the former 
was used in vivo, lymphocytosis as a result of the egress of CLL cells from proliferation centres would be observed.
In conclusion, although these studies cannot demonstrate relationship between Lck expression and clinical 
outcome in CLL, they are nevertheless important to our understanding of this disease. CLL cells are known 
to express various elements specific to the T cell receptor signalling pathway including Lck22,23, ZAP7018,35 and 
SLP7655. Interestingly, SLP76 is a scaffold protein and ZAP70 acts as a scaffold where it is expressed in CLL34,36, 
and both these proteins are substrates of Lck to suggest a potential relationship with respect to BCR signalling 
enhancement. In terms of the current study we were not able to test whether Lck expression levels refine disease 
prognosis in ZAP70 + CLL cases because too few cases were characterised for this protein. Considering that inhi-
bition of Lck (with Lck-i) and of PI3Kδ (with idelalisib) produce mechanistically similar effects, determination 
of Lck expression in ZAP70 + CLL cases may be useful for patient stratification strategies to receive idelalisib.
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Materials and Methods
Patient samples. Buffy coats used for this study were obtained from National Health Service Blood 
Transfusion. CLL cells were obtained from the peripheral blood taken from patients with informed consent and 
with the approval of the Liverpool and Hull Research Ethics Committees. Stored CLL cell samples from the 
Liverpool Leukaemia Biobank and Hull-York Medical School CLL Biobank were prepared using standard pro-
tocols as described previously56,57, and had a minimum viability of 80%. CLL sample usage and experiments 
performed on these samples were recorded in compliance with a Research Ethics Agreement overseen by the 
University of Liverpool and Royal Liverpool and Broadgreen NHS University Hospital Trust.
Measurement of Lck expression by Western blot. Normal human B cells were purified from buffy 
coats using the B Cell Isolation kit II (MACS, Miltenyi Biotec, Surry, U.K.) according to the manufacturer’s 
instructions. Purity of the B cells isolated by negative selection was checked using flow cytometry and CD19 
staining. In general, B cells treated in this way attained a purity that was greater than 90%. CLL cells were also 
negatively purified in a similar manner except that FITC-conjugated anti-CD3, -CD14, and -CD16 antibodies 
(BD Biosciences, Oxford, UK) were employed to separate T cells, NK cells, monocytes and macrophages using 
anti-FITC microbeads. CLL cell purity was checked using flow cytometry and CD5/CD19 staining. In general, 
CLL cells treated in this way attained a purity that was greater than 95%.
Cell pellets were prepared by lysing 1 × 107 cells with 200 μl of lysis buffer (125 mM Tris pH6.8, 5 mM EDTA, 
1%SDS). The lysates were sonicated to disrupt released DNA, incubated at 95 °C for 5–10 minutes and then centri-
fuged at 12,000 rpm for 5 minutes. The supernatant was transferred into a clean microtube and protein concentra-
tion was determined using the BioRad DC™ protein assay according to the manufacturer’s instructions (BioRad 
Laboratories Ltd, Hertfordshire U.K.). The lysates were stored at −20 °C until needed for further use.
To perform the Western blots 10 µg of total protein within cell lysates was loaded per lane of gel, and sep-
arated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using 10% polyacrylamide gels. The 
separated proteins were then electroblotted to ImmobilonTM membranes (Millipore, Fisher Scientific UK Ltd, 
Loughborough, UK). The membranes where then incubated for 1 h with blocking buffer [2.5% ECL advance 
blocking reagent (Millipore, Fisher Scientific UK Ltd, Loughborough, UK) in TBS-T (150 mM NaCl, 25 mM 
Tris pH 7.5, 0.1% Tween 20)], and then probed overnight at 4 °C with anti-Lck mAbs (clone 3A5, Santa Cruz 
Biotechnology, Insight Biotechnology Ltd, Wembley U.K.) diluted 1:1000 with blocking buffer. Following a sec-
ond 1 hour incubation with horse radish peroxidase (HRP)-conjugated anti-mouse antibodies (diluted 1/5000 
in blocking buffer), the membranes were thoroughly washed and then developed with ECL-advance Western 
Blotting Detection reagents (Millipore, Fisher Scientific UK Ltd, Loughborough, UK). Chemiluminescence was 
read using a Fujifilm LAS-1000 and Lck within cell lysates was quantitated against a standard curve of known 
amounts of recombinant Lck (R&D Systems Abingdon U.K.).
Measurement of Lck expression by flow cytometry. 5 × 106 cells were fixed and permeabilised 
using Phosflow™ fix and permeabilisation buffer II (BD) according to the manufacturer’s instructions. Cells 
were then incubated with incubated with PE-conjugated anti-Lck (clone MOL 171), FITC-conjugated anti-CD3, 
APC-conjugated anti-CD5 and PerCPCy5.5-conjugated CD19 mAbs (all from Becton Dickinson, Abbingdon, 
UK). The stained cells were then washed with modified PBS and analysed using a BD Fortessa flow cytometer. Lck 
expression in target cells (measured as mean fluorescence) was standardised against that in normal T cells within 
a sample from a single donor. This sample, derived from a buffy coat, was used, along with samples from a single 
CLL case, as a staining control to insure experimental reproducibility.
Measurement of S1PR1 expression by flow cytometry. Cells were simultaneously stained with 
directly conjugated mAbs to S1PR1 (clone 218713, PE conjugated; R&D Systems) and CD19 (PerCP-Cy5.5 con-
jugated; BD Biosciences, Oxford, U.K.) together with appropriate isotypic control Abs and analysed by multicolor 
flow cytometry. The percentage and mean fluorescence intensity for S1PR1 was determined on CD19+ cells. In 
addition, viability of the cells after culture was assessed using propidium iodide. None of the drugs used decreased 
the viability of CLL cells following culture. Because cells were cultured in conditions to minimize cell death, via-
bility was >75% in the majority of cases.
Migration assays. HUVECs were grown to confluence on the inserts of Transwell plates (5 μm pore size; 
Corning, High Wycombe, U.K.). Chemokines, S1P (Sigma-Aldrich) or CCL21 (R&D Systems), were added to 
the bottom wells at concentrations (100 ng/ml and 1 μg/ml, respectively) shown to induce maximum migration27. 
CLL cells were added to the inserts, and the number of B cells that had migrated to the bottom wells was counted 
after 6 h incubation. The migration index (number of CD19+ cells transmigrating with chemokine divided 
by number of cells transmigrating in the absence of chemokine) was then calculated. Idelalisib, ibrutinib and 
4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2d] pyrimidin -7-yl-cyclopentane (Lck-i) were all used at a final 
concentration of 1 μM.
Statistical analysis. Statistical analyses for this study were performed using SPSSv12™ and Microsoft 
Excel™ software packages.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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